Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 93

Sort by

Sort Order Select

Journal Articles

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Haris Ali, MD, David Snyder, MD, Tracy Stiller, MS, Timothy Synold, PhD, Saloomeh Mokhtari, Joycelynne Palmer, PhD, Amandeep Salhotra, MD, Vinod A. Pullarkat, MD, Ji-lian Cai, MD, Stephen J Forman, MD, Matthew Mei, MD, Ryotaro Nakamura, MD

Blood (2019) 134 (Supplement_1): 669.

https://doi.org/10.1182/blood-2019-127445

Published: 2019

Journal Articles

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

Claire N Harrison, Professor, Jacqueline S Garcia, MD, Ruben A Mesa, MD, Tim CP Somervaille, MD PhD, Rami S. Komrokji, MD, Naveen Pemmaraju, MD, Catriona Jamieson, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, James M. Foran, MD, Casey L. O'Connell, MD, Leanne Holes, BS, MBA,, Jia Jia, PhD MBA, Jason Harb, PhD, Jessica Hutti, PhD, Josef T. Prchal, MD

Blood (2019) 134 (Supplement_1): 671.

https://doi.org/10.1182/blood-2019-130158

Published: 2019

Journal Articles

Homozygosity for -2518 G Allele Variant of MCP-1 Predisposes to Adverse Presentation and Outcome in Primary Myelofibrosis

Elena Masselli, MD, Cecilia Carubbi, PhD, Giulia Pozzi, MS, Antonio Percesepe, MD PhD, Rita Campanelli, Laura Villani, Giuliana Gobbi, PhD, Vittorio Rosti, MD, Margherita Massa, Giovanni Barosi, Marco Vitale, MD

Blood (2019) 134 (Supplement_1): 1689.

https://doi.org/10.1182/blood-2019-122750

Published: 2019

Journal Articles

Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative Neoplasms

Pinkal Desai, MDMPH, Niamh Savage, BA, Spencer Krichevsky, BS, Tania Curcio, Sangmin Lee, MD, Michael B. Samuel, MD, Ellen K. Ritchie, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 1666.

https://doi.org/10.1182/blood-2019-127663

Published: 2019

Journal Articles

Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group

Blood (2019) 134 (Supplement_1): 2946.

https://doi.org/10.1182/blood-2019-124854

Published: 2019

Journal Articles

Advantages of Single Nucleotide Polymorphism(SNP)Array Based Karyotyping in Detection of Chromosomal Defects Combined with Metaphase Cytogenetics in Myelodysplastic Syndromes (MDS)

Yang Ou, Hongbin Yu, Yu Wu, MD

Blood (2019) 134 (Supplement_1): 5424.

https://doi.org/10.1182/blood-2019-126245

Published: 2019

Journal Articles

Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes

Andrew T Kuykendall, MD, Chetasi Talati, MD, Kendra L. Sweet, MD, Eric Padron, MD, David A Sallman, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD

Blood (2019) 134 (Supplement_1): 4177.

https://doi.org/10.1182/blood-2019-123536

Published: 2019

Journal Articles

Veno-Occlusive Disease (VOD) after Hematopoietic Stem Cell Transplant (HSCR): Always a Catastrophic Illness?

Paolo Bernasconi, MD, Anna Amelia Colombo, MD, Daniela Caldera, MD, Oscar Borsani, MD

Blood (2019) 134 (Supplement_1): 5649.

https://doi.org/10.1182/blood-2019-125608

Published: 2019

Journal Articles

Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib

Jennifer O'Sullivan, MD, Jason A Taylor, MD PhD, Aaron T. Gerds, MD MS, Sarah A Buckley, MD, Claire N Harrison, Professor, Stephen T. Oh, MD, Kieran Howard, Helene Marie-Pierre Dreau, PhD, Angela Hamblin, MD PhD, Adam J. Mead, MD PhD

Blood (2019) 134 (Supplement_1): 4214.

https://doi.org/10.1182/blood-2019-129254

Published: 2019

Journal Articles

The Study of Thrombosis in JAK2 V617F Mutated Myeloproliferative Neoplasms

Jie Bai, MD, Yuhui Zhang, Yingshao Wang, Guangshuai Teng, Yan Wang, Chenxiao Du, Yafang Chen, Huiqin Zhang, Yanqi Li, Lixia Fu, Lei Zhang, MD, Yuan Zhou, PhD

Blood (2019) 134 (Supplement_1): 1149.

https://doi.org/10.1182/blood-2019-125429

Published: 2019

Journal Articles

Arterial Function Deterioration Is Accelerated in Patients with Essential Thrombocythemia

Ajda Anzic Drofenik, MD, Matjaz Sever, MD PhD, Irena Zupan, MD PhD, Matjaz Vrtovec, MD PhD, Ales Blinc, MD PhD

Blood (2018) 132 (Supplement 1): 2417.

https://doi.org/10.1182/blood-2018-99-111862

Published: 2018

Journal Articles

Combination of Momelotinib and Citarinostat Show Strong Synergistic Effect in Lymphoid Cell Lines Co-Targeting JAK2/STAT3 and HDAC6

Maria Cosenza, MS, Monica Civallero, PhD, Stefano Sacchi, MD, Samantha Pozzi, MD

Blood (2018) 132 (Supplement 1): 3506.

https://doi.org/10.1182/blood-2018-99-116468

Published: 2018

Journal Articles

Comprehensive Clinical-Molecular Transplant Risk Model for Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation

Nico Gagelmann, Markus Ditschkowski, Rashit Bogdanov, Marie Robin, MD PhD, Bruno Cassinat, PharmD, PhD, Michael Heuser, MD, Rabia Shahswar, Felicitas Thol, MD, Dietrich W. Beelen, Anita Badbaran, Nicolaus Kroeger

Blood (2018) 132 (Supplement 1): 689.

https://doi.org/10.1182/blood-2018-99-114636

Published: 2018

Journal Articles

Initial Therapy of Polycythemia Vera (PV) with Interferon Alfa (rIFNa) Compared to Hydroxyurea (HU) or Phlebotomy Only (PHL-O) Is Associated with a Lower Risk of Secondary Myelofibrosis

Ghaith Abu-Zeinah, MD, Spencer Krichevsky, BS, Claudia Sosner, BA, Niamh Savage, BA, Joseph Scandura, MD PhD, Richard T. Silver, MD

Blood (2018) 132 (Supplement 1): 4316.

https://doi.org/10.1182/blood-2018-99-115520

Published: 2018

Journal Articles

Myeloproliferative Neoplasm (MPN) Driver Mutations Are Enriched during Hematopoietic Stem Cell Differentiation in Patterns That Correlate with Clinical Phenotype and Treatment Response

Ghaith Abu-Zeinah, MD, Silvana Di Giandomenico, PhD, Claudia Sosner, BA, Niamh Savage, BA, Spencer Krichevsky, BS, Ellen K. Ritchie, MD, Pouneh Kermani, PhD, Richard T. Silver, MD, Joseph Scandura, MD PhD

Blood (2018) 132 (Supplement 1): 4317.

https://doi.org/10.1182/blood-2018-99-117744

Published: 2018

Journal Articles

CD34+Selected Hematopoietic Stem Cell Transplants Conditioned with a Myeloablative Regimen Is Well Tolerated and Results in Good Outcomes in Patients with Myelofibrosis

Jeong-Ok Lee, MD, Jessica Flynn, BS, Molly Maloy, MS, Ann A. Jakubowski, MD PhD, Esperanza B. Papadopoulos, MD, Christina Cho, MD, Doris Ponce, MD, Craig S. Sauter, MD, Miguel-Angel Perales, MD, Sean M Devlin, PhD, Sergio Giralt, MD, Hugo R. Castro-Malaspina, MD, Roni Tamari, MD

Blood (2018) 132 (Supplement 1): 4636.

https://doi.org/10.1182/blood-2018-99-113166

Published: 2018

Journal Articles

Driver Mutation Profile By MLPA in Myelofibrosis Patients

Minuncio Juliana, MD, Alexandre Nonino, MD, Juliana Forte Mazzeu, PhD, Cintia do Couto Mascarenhas, MD PhD

Blood (2018) 132 (Supplement 1): 5494.

https://doi.org/10.1182/blood-2018-99-119776

Published: 2018

Journal Articles

Reduced Intensity Allogeneic Stem Cell Transplantation for Younger Patients with Myelofibrosis

Daniele Mannina, MD, Christine Wolschke, MD, Tatjana Zabelina, MD, Gaby Zeck, Ute-Marie von Pein, MD, Francis Ayuketang Ayuk, MD, Nicolaus Kroeger, MD

Blood (2018) 132 (Supplement 1): 5783.

https://doi.org/10.1182/blood-2018-99-112137

Published: 2018

Journal Articles

Niche Heterogeneity Impacts Evolution of Myeloproliferative Neoplasms Driven By the Same Oncogenic Pathway

Blood (2018) 132 (Supplement 1): 98.

https://doi.org/10.1182/blood-2018-99-113495

Published: 2018

Journal Articles

Single-Cell RNA Sequencing Discloses Distinct Transcriptomic Profiling in Essential Thrombocythemia

Chia-Chen Hsu, PhD, Cih-En Huang, MD, Ying-Ju Chen, Yuying Wu, MD, Hsing-Yi Tsou, Chian-Pei Li, Wei-Hsuan Chuang, Yi-Hua Lai, Yi-Hsuan Lin, Chih-Cheng Chen, MD

Blood (2018) 132 (Supplement 1): 3061.

https://doi.org/10.1182/blood-2018-99-113990

Published: 2018

NARROW

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

Homozygosity for -2518 G Allele Variant of MCP-1 Predisposes to Adverse Presentation and Outcome in Primary Myelofibrosis

Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative Neoplasms

Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group

Advantages of Single Nucleotide Polymorphism(SNP)Array Based Karyotyping in Detection of Chromosomal Defects Combined with Metaphase Cytogenetics in Myelodysplastic Syndromes (MDS)

Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes

Veno-Occlusive Disease (VOD) after Hematopoietic Stem Cell Transplant (HSCR): Always a Catastrophic Illness?

Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib

The Study of Thrombosis in JAK2 V617F Mutated Myeloproliferative Neoplasms

Arterial Function Deterioration Is Accelerated in Patients with Essential Thrombocythemia

Combination of Momelotinib and Citarinostat Show Strong Synergistic Effect in Lymphoid Cell Lines Co-Targeting JAK2/STAT3 and HDAC6

Comprehensive Clinical-Molecular Transplant Risk Model for Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation

Initial Therapy of Polycythemia Vera (PV) with Interferon Alfa (rIFNa) Compared to Hydroxyurea (HU) or Phlebotomy Only (PHL-O) Is Associated with a Lower Risk of Secondary Myelofibrosis

Myeloproliferative Neoplasm (MPN) Driver Mutations Are Enriched during Hematopoietic Stem Cell Differentiation in Patterns That Correlate with Clinical Phenotype and Treatment Response

CD34+Selected Hematopoietic Stem Cell Transplants Conditioned with a Myeloablative Regimen Is Well Tolerated and Results in Good Outcomes in Patients with Myelofibrosis

Driver Mutation Profile By MLPA in Myelofibrosis Patients

Reduced Intensity Allogeneic Stem Cell Transplantation for Younger Patients with Myelofibrosis

Niche Heterogeneity Impacts Evolution of Myeloproliferative Neoplasms Driven By the Same Oncogenic Pathway

Single-Cell RNA Sequencing Discloses Distinct Transcriptomic Profiling in Essential Thrombocythemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only